Charles Large
Company: Autifony Therapeutics
Job title: Chief Executive Officer
Seminars:
Live Q&A Session with Your Expert Speakers 4:30 pm
day: Day One
Precision Medicine with Kv3 Channel Modulators: Matching Mechanism to Patient Pathophysiology 3:00 pm
• Development of Kv3 channel modulators for the treatment of rare neurodevelopmental disorders, such as Fragile X Syndrome and genetic epilepsies • Matching the target and drug mechanism to the most appropriate patient populations • Selecting mechanism and disease-relevant biomarkers such as EEG, auditory evoked potentials, or TMSRead more
day: Day One